[1-(3-dipropylcarbamoyl-benzoylamino)-2-phenyl-ethyl]-(2-phenyl-2-p-tolylcarbamoyl-ethyl)-phosphinic acid | 851914-19-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: [1-(3-dipropylcarbamoyl-benzoylamino)-2-phenyl-ethyl]-(2-phenyl-2-p-tolylcarbamoyl-ethyl)-phosphinic acid
• 英文别名: [1-[[3-(Dipropylcarbamoyl)benzoyl]amino]-2-phenylethyl]-[3-(4-methylanilino)-3-oxo-2-phenylpropyl]phosphinic acid
• CAS: 851914-19-7
• 化学式: C₃₈H₄₄N₃O₅P
• 分子量: 653.758
• InChiKey: UEZHUUCKADRWHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  47
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Phosphinic acids
  申请人：Hilpert Hans

  公开号：US20050107341A1

  公开（公告）日：2005-05-19

  The present invention relates to phosphinic acid derivatives of formula I wherein R 1 , R 2 , R 3 and R 4 are described hereinabove. These compounds can be used in the treatment or prevention of a disease related to the inhibition of β-secretase, inter alia for the treatment of Alzheimer's disease.

  本发明涉及式I的膦酸衍生物，其中R1、R2、R3和R4如上所述。这些化合物可用于治疗或预防与β-分泌酶抑制有关的疾病，包括治疗阿尔茨海默病。
• PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1685142A1

  公开（公告）日：2006-08-02
• US7345082B2
  申请人：——

  公开号：US7345082B2

  公开（公告）日：2008-03-18
• [EN] PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES D'ACIDE PHOSPHINIQUE, INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005044830A1

  公开（公告）日：2005-05-19

  The present invention relates to phosphinic acid derivatives of formula (I) wherein R1 is aryl or heteroaryl, R2 is (C1-C5)-alkyl or phenyl, R3 is hydrogen, (C1-C5)-alky, O-(C1-C5)-alkyl or phenyl, R4 is (C1-C6)-alkyl, (C3-C6)-cycloalkyl, phenyl, pyridyl or indolyl, and pharmaceutically acceptable salts thereof. The compounds can be used in the treatment or prevention of a disease related to the inhibition of beta-secretase, inter alia for the treatment of Alzheimer’s disease.